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INTRODUCTION
Worldwide there are approximately 600 000 new cases of
head and neck cancer registered yearly (Dayyani et al.,
2010). That makes this region of the body to be the 6th most
common for cancer to appear in. The incidence of hypopha-
ryngeal cancer is relatively low globally — 0.8 per 100 000
(1.4 in men and 0.3 in women) (Shield et al.,, 2017). Most
head and neck cancers are squamous cell carcinomas
(SCC).
In the last 20 years, the association between head and neck,
especially, oropharyngeal squamous cell carcinoma and the
presence of human papillomavirus (HPV) infection, has
been established (Gillison et al., 2000; Gillison and Shah,
2001; Veyer et al., 2019). Globally, every year approxi-
mately 38 000 cases of head and neck cancers are consid-
ered to be HPV-related (Plummer et al., 2016; de Martel et
al., 2017). HPV16 and 18 have been generally recognised
as the most frequent causative HPV types in head and neck
cancer, particularly oropharyngeal SCC (Anonymous, 2007;
Gillison et al., 2014; 2015; de Martel et al., 2017). There is
still a pending question on the significance of the role of
HPV infection in the development of hypopharyngeal and
laryngeal SCC (Dahm et al., 2018). It was reported that
about 5–7% of laryngeal cancers and as low as 0% of hy-
popharyngeal cancers were associated with high-risk (HR)
HPV infection (Combes and Franceschi 2014; Plummer et
al., 2016).
Of all head and neck SCC, hypopharyngeal manifests most
aggressively. Conventionally, diagnosis is made based on
histopathological examination of the tumour. Often, the
amount of tissue is limited for extended examination, in-
cluding for DNA and RNA extraction and testing. Even
greater hurdles appear when biopsy material is formalin-
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The incidence of hypopharyngeal cancer globally is about 0.8 per 100 000. Globally, approxi-
mately 38 000 cases of head and neck cancer are considered yearly to be high-risk human
papillomavirus (HR-HPV) related. Biopsy material fixation in formalin and embedding in paraffin
(FFPE) creates many challenges. The extraction of nucleic acid material requires a more compli-
cated approach, and often the extracted DNA is fragmented. The aim of the study was to com-
pare several HR-HPV detection methods in nucleic acid material extracted from FFPE samples.
The extracted DNA was analysed with different molecular biology methods to assess DNA quality
and to determine the presence of HPV DNA with various HPV detection systems. The results
were compared and statistically analysed. There was good agreement between two real-time
PCR methods — Anyplex II HPV28 and Sacace HPV High-Risk Screen Real-TM Quant. We
failed to reach a conclusion on agreement between real-time PCR methods and HPV16 type-spe-
cific primer PCR. There was moderate positive correlation between Anyplex II HPV28
semiquantitative results and Sacace quantitative results. We suggest that real-time PCR assays
detecting smaller DNA amplicons are good and reliable methods for detecting HPV genetic mate-
rial in FFPE samples.
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fixed and embedded in paraffin (FFPE). Furthermore, DNA
appears fragmented when applying a complicated approach
for extracting nucleic acid material.
Fortunately, the development of FFPE DNA extraction kits
has allowed the use of molecular biology methods for
analysis of materials that have been stored for a long period
and have small size.
Therefore, this study aimed to compare several methods of
HR-HPV assessment in nucleic acid material extracted from
hypopharyngeal SCC FFPE samples and to test different de-
tection systems.
MATERIALS AND METHODS
Clinical material. We carried out a retrospective study of
31 patients diagnosed with hypopharyngeal SCC, staged
following the TNM classification of the International Union
against Cancer (7th edition), and treated in Rîga East Clini-
cal University Hospital, Stationary Oncology Centre of Lat-
via. The patients’ data were collected from the Hospital Ar-
chive.
Collection of biopsy samples and tissue processing. Hy-
popharynx biopsy samples from patients hospitalised in
Rîga East Clinical University Hospital, Oncology Centre of
Latvia, were acquired between 2015 and 2019. All included
patients belonged to a cohort declared and approved by
Rîga Stradiòð University Ethics Committee (Decision No.
3/24.09.2015). The diagnosis of hypopharyngeal SCC was
histopathologically confirmed. Biopsies were taken prior to
treatment. Three to six 10 µm thick sections cut from FFPE
samples were used for DNA extraction. Each sample was
sectioned separately with a clean blade to exclude cross-
contamination of specimens.
DNA extraction. Thirty-one hypopharyngeal SCC FFPE
samples were used for DNA extraction with a blackPREP
FFPE DNA Kit (Analytik Jena, Germany) in accordance
with the manufacturer’s protocol.
The quality and quantity of DNA were estimated spectro-
metrically (Nanodrop ND-1000 Spectrophotometer, Thermo
Fisher Scientific, Waltham, MA, USA). Beta- (-) globin
PCR with appropriate primers was used to determine the
quality of isolated DNA (Vandamme et al., 1995). Only
-globin positive samples were used for further analysis.
HPV DNA detection using MY09/11 and GP5+/6+ con-
sensus primers. Polymerase chain reaction (PCR) with
consensus primers MY9/MY11 and GP5+/6+ was used to
detect the range of HR-HPV and low-risk HPV (LR-HPV)
types (Shikova et al., 2009; ªahiner et al., 2014). The re-
sults were visualised by electrophoresis in 1.7% agarose
gel. Amplification products of 450 base pairs (bp) and 150
bp length for MY09/11 and GP5+/6+ correspondingly were
considered HPV positive. Positive and negative controls
were included in each reaction.
HPV genotyping using isolated HPV16 and HPV18
primers. The primers used to detect HPV16 and HPV18
specific genomic sequences are summarised in Table 1
(Shikova et al., 2009). Amplification using HPV16 specific
primers produces 152 bp long amplicons and using HPV18
specific primers — 216 bp amplicons. The results were
visualised by electrophoresis in 1.7% agarose gel. Reactions
were performed with the use of positive and negative con-
trols. Positive and negative controls were included in each
reaction.
HPV detection and genotyping by Anyplex II HPV28.
Anyplex II HPV28 multiplex real-time PCR (RT-PCR) was
performed as recommended by the manufacturer (Seegene,
South Korea). A specimen of 5 µl DNA was added in each
of two sets (wells) with 20-µl PCR reaction mix. Set A con-
sisted of primer mix for 14 HR-HPV types (HPV16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), and set B
consisted of primer mix for five possible HR-HPV types
(HPV26, 53, 69, 73, and 82) and nine LR- HPV types
(HPV6, 11, 40, 42, 43, 44, 54, 61, and 70). Both primer sets
were designed for the HPV L1 gene and produced 100 and
200 bp long amplicons, respectively.
Melting curves were obtained at 30, 40, and 50 cycles al-
lowing semiquantitative specimen analysis and differentiat-
ing between high (+++), medium (++), or low (+) viral
loads, and there were internal positive and negative con-
trols. The kit had DNA quality control by detecting the
-globin gene. The results were analysed using the Seegene
Viewer software (Seegene).
HPV detection by Sacace HPV High-Risk Screen Real-
TM Quant. HPV High-Risk Screen Real-TM Quant
(Sacace Biotechnologies, Italy) is an in vitro real-time am-
plification test for quantitative detection of HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59. It includes mixture
of primer for HPV groups A7, A9 (HPV16, 18, 31, 33, 35,
39, 45, 52, 58, 59), HPV group A5 (HPV51), and HPV
group A6 (HPV56), and has an internal control (-globin
gene). The kit contains quantitative standards with the
known concentration of HPV DNA, used for calculation of
the viral load.
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Statistical data analysis. Seegene results were assessed
semiquantitatively and coded as follows: 1 – negative; 2 –
for +; 3 – for ++; and 4 – for +++. Viral load (copies/105
cells) from the Sacace assay was expressed in log10 and
submitted to statistical analysis. For negative samples, log10
random values of 0 (viral load of approximately 1 cop-
ies/105 cells) as a mean and SD of 0.1 were assigned (gen-
erated with GraphPad Prism random number generator).
Cohen’s  test was used to assess agreement between the
HPV detection methods with 1 – indicating perfect agree-
ment; 1 to 0.81 – very good agreement; 0.80 to 0.61 – good
agreement; and 0.60 to 0.21 – moderate to a poor agree-
ment.
The Mann–Whitney test was used to assess if the differ-
ences of nonparametric data were significant. Relations be-
tween viral load (Sacace assay) and semiquantitative results
(Anyplex assay) were investigated using nonparametric
Spearman’s correlation analysis (Mukaka, 2012; Akoglu,
2018).
A nonlinear regression model was used to graphically as-
sess the relationship between the viral load and the
semiquantitative results of Anyplex II HPV28 assay.
RESULTS
Thirty-one patients with hypopharyngeal SCC were in-
cluded in this study. Most patients were male (93.5%, n =
29), with only two female patients (6.5%). The mean patient
age was 66.3 years (range 44-83.3), median — 65.2 years.
Unfortunately, all of the patients presented with advanced
disease stage — 11 (35.5%) with stage III, and 20 (64.5%)
— with stage IV.
DNA extraction from FFPE samples was an easy and not
time-consuming procedure when using the blackPREP
FFPE DNA Kit. The lowest extracted DNA concentration
was 16.54 ng/µl; in most of the extracted DNA samples the
concentration was above 60 ng/µl. All extracted DNA sam-
ples were -globin gene-positive, which made them viable
for further analysis.
Of the 31 hypopharyngeal SCC FFPE samples, only 1 was
positive for HPV using MY09/11 consensus primers. In
contrast, GP5+/6+ consensus primers were much more effi-
cient with positivity of 100% (n = 31) for HPV DNA.
Further HPV genotyping using HPV16 and HPV18 specific
primers showed positivity for HPV16 only. Of 31 samples,
15 (48.4%) were positive for HPV16.
Anyplex II HPV28 assay showed HPV positivity for 14
(45.2%) samples. In one case, there was co-infection by 2
HPV types (type 16 and 56), with the remaining 13 cases
positive for HPV16.
The Sacace HPV High-Risk Screen Real-TM Quant test
showed HPV positivity for 12 (38.7%) samples in HEX
channel, which corresponded to the HPV A9 group (16, 31,
33, 35, 52, 58).
Comparison of HPV detection and genotyping results
between HPV16 specific primers, Anyplex II HPV28 as-
say, and Sacace HPV High-Risk Screen Real-TM Quant.
The same DNA extracts from the 31 selected FFPE samples
tested by GP5+/6+ and HPV16 specific primers, were fur-
ther subjected to Anyplex II HPV28 assay, and Sacace HPV
High-Risk Screen Real-TM Quant assay. Valid results with
the use of both assays were obtained for all 31 biopsy sam-
ples.
Although, HPV16 specific primers’ PCR and Anyplex as-
say showed similar positivity in overall count sense (15/14
positive out of 31), only 9 cases were identical. The remain-
ing positive cases were discordant, meaning cases positive
in PCR with HPV16 specific primers were negative in
Anyplex II HPV28 assay, and vice versa. We could not as-
sess the agreement of both tests because of the high p-value
of Cohen’s kappa (Cohen’s  coefficient = 0.288, p =
0.156). Comparison of the results from PCR with HPV16
specific primers and Sacace assay showed a similar result
(Cohen’s  coefficient = 0.285, p = 0.149), meaning that the
agreement between these two methods could not be as-
sessed with significance.
Among the 14 HPV-positive samples by Anyplex assay, 11
(78.6%) were found positive by the Sacace assay. Simulta-
neously, three samples positive in Anyplex assay were neg-
ative in Sacace assay. One sample was positive in the
Sacace assay while negative in the Anyplex assay. The
agreement between both methods was good (Cohen’s  co-
efficient = 0.736, p < 0.001)
HPV viral load. As previously mentioned, HPV High-Risk
Screen Real-TM Quant (Sacace Biotechnologies, Italy) is
an in vitro real-time amplification test for quantitative de-
tection of HPV. Although it does not specifically show the
type of HPV, it has three channels for different types of
HPV. The analysed samples showed positive signals in the
HEX channel only, which corresponded to HPV16.
There was a moderate positive correlation between viral
load (assessed by Sacace assay) and semiquantitative See-
gene assay results estimated semiquantitatively (Spearman’s
correlation coefficient = 0.60, CI 0.30–0.79, p = 0.0004),
Figure 1.
Fig. 1. Correlation between two RT-PCR assays.
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DISCUSSION
All methods were used on the same DNA extracts, which
makes the results highly accurate and applicable for assess-
ment of agreement between different HPV detection meth-
ods.
As shown in different studies, the Anyplex II HPV28 assay
is an appropriate and dependable HPV detection method
with good sensitivity and specificity (Cornall et al., 2017;
Del Pino et al., 2017; Baasland et al., 2019; Veyer et al.,
2019). However, there has been data acknowledging the
need for additional conformational HPV16 genotype-spe-
cific molecular assay, especially for HPV-negative samples
(Veyer et al., 2019). In our study we were unable to surely
conclude agreement/disagreement between Anyplex II as-
say and HPV16-specific primer PCR results. Simulta-
neously, we had multiple HPV16 positive samples by
HPV16 specific primers’ PCR, diagnosed as negative in
Anyplex II HPV28 assay and vice versa. This suggests the
need for multiple detection methods for FFPE DNA ex-
tracts.
Previous studies have demonstrated that genetic material
extracted from FFPE is highly variable in terms of DNA
quality and quantity (Lillsunde Larsson et al., 2015). Vari-
ous factors can affect the results of assessment – reagents
used in a fixation procedure, the amount of tissue submitted
to fixation and further tissue processing, etc. (Srinivasan et
al., 2002; Ludyga et al., 2012). This applies even more for
hypopharyngeal biopsy material, as biopsies are performed
using local anesthetic with indirect visualisation. Neverthe-
less, our results show that even small amounts of DNA con-
centration can be successfully used for HPV DNA detec-
tion.
MY09/11 consensus primers produce 450 bp long
amplicons. In our study, we had only one (of a total of 31)
HPV-positive specimens with the use of these primers. In
contrast, GP5+/6+ primers produce 150 bp long amplicons,
which resulted in 100% positivity in our study. Therefore,
we suggest that primers for shorter HPV DNA amplicons
are more beneficial, especially in fragmented DNA ex-
tracted from FFPE samples.
Our observations demonstrate that Anyplex II HPV28 and
Sacace HPV High-Risk Screen Real-TM Quant assays can
be used in a clinical laboratory to detect and genotype HPV
in FFPE samples. The combination of these two assays has
a beneficial effect when detecting different HPV types and
estimating the viral load.
In conclusion, it seems that RT-PCR assays detecting
smaller DNA amplicons are good and reliable for detecting
HPV genetic material in FFPE samples. However, confir-
mation of HPV detected using additional HPV methods
may be applicable when searching for overall sensitivity.
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CILVÇKA PAPILOMAS VÎRUSA (CPV) NOTEIKÐANA UN TIPÇÐANA HYPOPHARYNX PLAKANÐÛNU KARCINOMAS
PARAUGOS
Hypopharynx vçþa ikgadçja pasaules incidence ir aptuveni 0,8 uz 100 000. Tiek uzskatîts, ka aptuveni 38 000 galvas un kakla vçþa
gadîjumu ir CPV infekcijas izraisîti. Ir daudz grûtîbu, kas saistîtas ar biopsijas materiâla, kas fiksçts formalînâ un ieguldîts parafînâ,
molekulâri bioloìisko analîzi. DNS izdalîðana no ðâdiem paraugiem bieþi vien ir laikietilpîga, grûtâka, un izdalîtâ DNS nereti ir
fragmentçta. Ðî pçtîjuma mçríis bija salîdzinât vairâkas augsta riska CPV noteikðanas metodes no parafîna blokiem izdalîtajâ ìençtiskajâ
materiâlâ. Tika noteikta izdalîtâs DNS kvalitâte, kâ arî CPV DNS klâtbûtne, izmantojot vairâkas CPV noteikðanas “sistçmas”. Rezultâti tika
salîdzinâti un statistiski analizçti. Starp divâm reâlâ laika polimerâzes íçdes reakcijas (PÍR) metodçm (Anyplex II HPV28 un Sacace HPV
High-Risk Screen Real-TM Quant) bija vçrojama laba sakritîba. Mçs nevarçjâm izdarît statistiski ticamus secinâjumus par rezultâtu
sakritîbu starp reâlâ laika PÍR metodçm un HPV16 specifisko praimeru PÍR. Daudziem paraugiem bija ne tikai identiski, bet arî pretçji
rezultâti ðo metoþu lietojumâ. Starp Anyplex II HPV28 puskvantitatîvajiem rezultâtiem un Sacace kvantitatîvajiem rezultâtiem bija mçrena
pozitîva korelâcija. Secinâjums: reâlâ laika PCR testi, ar kuru palîdzîbu var noteikt mazâkus DNS amplikonus, ir labas un uzticamas
metodes CPV ìençtiskâ materiâla noteikðanai parafîna bloku paraugos.
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